The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial led by UCL scientists. It successfully lowered the level of the harmful huntingtin protein in the nervous system.
After over a decade in pre-clinical development, this first human trial of huntingtin-lowering drug began in late 2015, led by Professor Sarah Tabrizi (UCL Institute of Neurology) and sponsored by Ionis Pharmaceuticals.
The trial involved enrolling 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada.
Each patient received four doses of either IONIS-HTTRx or placebo, given by injection into the spinal fluid to enable it to reach the brain. As the phase 1/2a trial progressed, the dose of IONIS-HTTRx was increased several times according to the ascending-dose trial design.
Patient safety was monitored throughout the study by an independent safety committee.
Today’s announcement at completion of the trial confirms that IONIS-HTTRx was well-tolerated by the trial participants and its safety profile supports further testing in patients.
Professor Tabrizi, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator, said: “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”
A major unknown was whether the trial would show that IONIS-HTTRx could lower the level of mutant huntingtin protein in the nervous system. Using an ultra-sensitive assay, concentrations of the protein were measured in each patient’s spinal fluid before and after treatment.
As hoped, IONIS-HTTRx produced significant, dose-dependent lowering of the level of mutant huntingtin – the first time the protein known to cause Huntington’s has been lowered in the nervous system of patients.
As a result of these successful outcomes, Ionis’ partner, Roche, has exercised its option to license IONIS-HTTRx and assumes responsibility for further development, regulatory activities and commercialization activities. Meanwhile, Ionis announced in June that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.
Learn more: Drug lowers deadly Huntington’s disease protein
The Latest on: Huntington’s disease
[google_news title=”” keyword=”Huntington’s disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Careon May 13, 2024 at 7:01 am
PhotoPharmics, the leader in specialized phototherapy for neurodegenerative diseases, today announced the successful enrollment of its first 25 patients into the Celeste Light for PD Trial. This ...
- Huntington's Disease Warning Signs: What To Look Out Foron May 10, 2024 at 2:28 pm
Overview A condition that leads to progressive degeneration of nerve cells in the brain that affects movement, cognitive functions, and emotions. Symptoms If you or someone you know is exhibiting ...
- Buy Rating Affirmed for uniQure Amid Strong Pipeline and Regulatory Progresson May 9, 2024 at 10:16 pm
Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on uniQure (QURE – Research Report) and decreased the price target ...
- A year on, Teva CEO Richard Francis celebrates progress in 'Pivot to Growth' planon May 8, 2024 at 12:02 pm
In about a year after launching a revamp strategy under CEO Richard Francis, Teva has managed to return its generics business to growth, secure approvals for a pair of high-profile biosimilars | While ...
- Join the 3rd Annual Golf for a Cure for Huntington’s Diseaseon May 8, 2024 at 10:21 am
The Massachusetts and Rhode Island Chapters of the Huntington’s Disease Society of America want you to help find a cure by joining this year’s golf for a cure ...
- Research suggests tear fluid testing as promising method for Huntington’s Disease monitoringon May 7, 2024 at 2:15 pm
Huntington's disease (HD) is an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age.
- Huntington’s Disease Treatment Market Value: Understanding Pricing and Valuation Trendson May 6, 2024 at 11:24 pm
The global Huntington?s disease treatment market revenue was around US$ 316.5 million in 2021 and is estimated to reach US$ 708.2 million by 2031, growing at a compound annual growth rate (CAGR) of ...
- Team Hope Walk raises awareness for Huntington’s Diseaseon May 5, 2024 at 1:54 am
Saturday for the Team Hope Statewide Walk. The walk was to raise money for Huntington’s Disease. Huntington’s disease is a rare, neurodegenerative disease that causes nerve cells in the brain to ...
- Leprosy drug may be effective in Huntington's disease, study suggestson May 3, 2024 at 6:16 am
A preclinical study from Karolinska Institutet offers hope for treating severe neurodegenerative diseases with an existing drug. The study suggests that the leprosy drug clofazimine may be effective ...
- US FDA approves Neurocrine Biosciences' movement disorder drugon May 2, 2024 at 7:22 am
The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' INGREZZA drug to treat movement disorders associated with Huntington's disease, the company ...
via Google News and Bing News